Florentine Hilbers
Florentine Hilbers
Breast International Group
Bestätigte E-Mail-Adresse bei bigagainstbc.org
TitelZitiert vonJahr
Rare mutations in XRCC2 increase the risk of breast cancer
DJ Park, F Lesueur, T Nguyen-Dumont, M Pertesi, F Odefrey, F Hammet, ...
The American Journal of Human Genetics 90 (4), 734-739, 2012
1532012
Whole exome sequencing suggests much of non-BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles
FJ Gracia-Aznarez, V Fernandez, G Pita, P Peterlongo, O Dominguez, ...
PloS one 8 (2), e55681, 2013
952013
FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor
P Peterlongo, I Catucci, M Colombo, L Caleca, E Mucaki, M Bogliolo, ...
Human molecular genetics 24 (18), 5345-5355, 2015
562015
Rare variants in XRCC2 as breast cancer susceptibility alleles
FS Hilbers, JT Wijnen, N Hoogerbrugge, JC Oosterwijk, MJ Collee, ...
Journal of medical genetics 49 (10), 618-620, 2012
442012
COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration
MC Southey, DJ Park, T Nguyen-Dumont, I Campbell, E Thompson, ...
Breast Cancer Research 15 (3), 402, 2013
342013
The impact of next generation sequencing on the analysis of breast cancer susceptibility: a role for extremely rare genetic variation?
FSM Hilbers, MPG Vreeswijk, CJ van Asperen, P Devilee
Clinical Genetics 84 (5), 407-414, 2013
332013
Exome sequencing of germline DNA from non-BRCA1/2 familial breast cancer cases selected on the basis of aCGH tumor profiling
FS Hilbers, CM Meijers, JFJ Laros, M van Galen, N Hoogerbrugge, ...
PloS one 8 (1), e55734, 2013
252013
Genetic variants in TGFβ-1 and PAI-1 as possible risk factors for cardiovascular disease after radiotherapy for breast cancer
FSM Hilbers, NB Boekel, AJ van den Broek, R van Hien, S Cornelissen, ...
Radiotherapy and Oncology 102 (1), 115-121, 2012
242012
Breast Cancer Family Registry, Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, Giles GG, Devilee P, Benitez J, Hopper JL, Tavtigian SV …
DJ Park, F Lesueur, T Nguyen-Dumont, M Pertesi, F Odefrey, F Hammet, ...
Am J Hum Genet 90 (4), 734-9, 2012
212012
Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2–positive early breast cancer: Analysis from the NeoALTTO …
M Lambertini, S Martel, C Campbell, S Guillaume, FS Hilbers, U Schuehly, ...
Cancer 125 (2), 307-316, 2019
162019
Functional Analysis of Missense Variants in the Putative Breast Cancer Susceptibility Gene XRCC2
FS Hilbers, MS Luijsterburg, WW Wiegant, CM Meijers, M Völker‐Albert, ...
Human mutation 37 (9), 914-925, 2016
72016
Abstract S3-02: Plasma microRNA levels for predicting therapeutic response to neoadjuvant treatment in HER2-positive breast cancer: Results from Neo-ALTTO
S Di Cosimo, V Appierto, P Tiberio, P Verderio, S Pizzamiglio, S Bottelli, ...
Cancer Research 77 (4 Supplement), S3-02-S3-02, 2017
42017
Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial
M Lambertini, C Campbell, RD Gelber, G Viale, A McCullough, F Hilbers, ...
Breast cancer research and treatment, 1-12, 2019
22019
Impact of body mass index (BMI) and weight change after treatment in patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Secondary analysis of the ALTTO BIG 2 …
S Martel, M Lambertini, D Agbor-Tarh, N Falbel Ponde, A Gombos, ...
Journal of Clinical Oncology 36 (15_suppl), 10067-10067, 2018
22018
Addition of a 161-SNP polygenic risk score to family history-based risk prediction: impact on clinical management in non-BRCA1/2 breast cancer families
IMM Lakeman, FS Hilbers, M Rodríguez-Girondo, A Lee, MPG Vreeswijk, ...
Journal of medical genetics, jmedgenet-2019-106072, 2019
12019
Exploratory analysis of the effect of taselisib on downstream pathway modulation and correlation with tumor response in ER-positive/HER2-negative early-stage breast cancer from …
P Nuciforo, D Hlauschek, C Saura, E de Azambuja, R Fasani, P Villagrasa, ...
Journal of Clinical Oncology 37 (15_suppl), 1050-1050, 2019
12019
152O First report of AURORA, the breast international group (BIG) molecular screening initiative for metastatic breast cancer (MBC) patients (pts)
PG Aftimos, AM Antunes De Melo e Oliveira, F Hilbers, D Venet, ...
Annals of Oncology 30 (Supplement_3), mdz100. 003, 2019
12019
Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial.
SC Di, V Appierto, S Pizzamiglio, P Tiberio, MV Iorio, F Hilbers, ...
Clinical cancer research: an official journal of the American Association …, 2019
12019
322TiPPYTHIA: A phase II study of palbociclib plus fulvestrant for pretreated patients with ER+/HER2-metastatic breast cancer
D Zardavas, M Regan, R Maibach, B Ruepp, A Hiltbrunner, L Blacher, ...
Annals of Oncology 28 (suppl_5), 2017
12017
An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06)
E Risi, C Biagioni, M Benelli, I Migliaccio, A McCartney, M Bonechi, ...
Therapeutic Advances in Medical Oncology 11, 1758835919891608, 2019
2019
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20